Indeed, Omomyc has been extensively characterized and validated in various cancer models, both as a transgene and as a mini-protein (for a historical perspective, refer to[65]) and demonstrated the feasibility, safety and dramatic therapeutic impact of MYC inhibition. The gene discussed is MYC; the disease is cancer.